54558 Federal Register / Vol. 70, No. 178 / Thursday, September 15, 2005 / Notices 

Submission of Written Information 

In general, individuals or 

organizations wishing to provide 

written information for consideration by 

the Citizens’ Health Care Working 

Group should submit information 

electronically to 

citizenshealth@ahrq.gov. The Working 

Group invites submissions on those 

topics to be addressed at the Working 

Group business meetings listed above. 

Since all electronic submissions will be 

posted on the Working Group web site, 

separate submissions by topic will 

facilitate review of ideas submitted on 

each topic by the Working Group and 

the public. 

Dated: September 1, 2005. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 05–18389 Filed 9–13–05; 9:47 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Notice of Meetings 

In accordance with section 10(d) of 

the Federal Advisory Committee Act as 

amended (5 U.S.C., Appendix 2), the 

Agency for Healthcare Research and 

Quality (AHRQ) announces meetings of 

scientific peer review groups. The 

subcommittees listed below are part of 

the Agency’s Health Services Research 

Initial Review Group Committee. 

The subcommittee meetings will be 

closed to the public in accordance with 

the Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b(c)(6). Grant 

applications are to be reviewed and 

discussed at these meetings. These 

discussions are likely to involve 

information concerning individuals 

associated with the applications, 

including assessments of their personal 

qualifications to conduct their proposed 

projects. This information is exempt 

from mandatory disclosure under the 

above-cited statutes. 

1. Name of Subcommittee: Health 

Care Research Training. 

Date: September 22–23, 2005 (Open 

from 8 a.m. to 8:15 a.m. on September 

22 and closed for remainder of the 

meeting). 

2. Name of Subcommittee: Health 

Research Dissemination and 

Implementation. 

Date: October 20–21, 2005 (Open from 

8 a.m. to 8:15 a.m. on October 21 and 

closed for remainder of the meeting). 

3. Name of Subcommittee: Health 

Systems Research. 

Date: October 20–21, 2005 (Open from 

8 a.m. to 8:15 a.m. on October 21 and 

closed for remainder of the meeting). 

4. Name of Subcommittee: Health 

Care Technology and Decision Sciences. 

Date: October 27–28, 2005 (Open from 

8 a.m. to 8:15 a.m. on October 27 and 

closed for remainder of the meeting). 

5. Name of Subcommittee: Health 

Care Quality and Effectiveness 

Research. 

Date: October 27–28, 2005 (Open 8 

a.m. to 8:15 a.m. on October 27 and 

closed for remainder of the meeting). 

All the meetings above will take place 

at: Agency for Healthcare Research and 

Quality, John Eisenberg Conference 

Center, 540 Gaither Road, Rockville, 

Maryland 20850. 

Contact Person: Anyone wishing to 

obtain a roster of members, agenda or 

minutes of the nonconfidential portions 

of the meetings should contact Mrs. 

Bonnie Campbell, Committee 

Management Officer, Office of 

Extramural Research, Education and 

Priority Populations, AHRQ, 540 

Gaither Road, Suite 2000, Rockville, 

Maryland 20850, Telephone (301) 427–

1554. Agenda items for these meetings 

are subject to change as priorities 

dictate. 

Dated: September 1, 2005. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 05–18388 Filed 9–13–05; 9:47 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Program Announcement 04065–

Supplement] 

Increasing Teen Driving Safety 

A. Purpose 

The Centers for Disease Control and 

Prevention (CDC) announces the intent 

to fund fiscal year (FY) 2005 

supplemental funds for a cooperative 

agreement program to provide support 

and assistance to the Society for 

Advancement of Violence and Injury 

Research (SAVIR), for the development 

and implementation of an intervention 

to encourage teen driver compliance 

with (and parental endorsement of) 

Graduated Driver Licensing restrictions 

on drivers who have an intermediate 

license—the group for which crash risk 

is highest among all drivers. 

B. Eligible Applicant 

Assistance will be provided to SAVIR. 

SAVIR is being targeted because they 

are uniquely qualified to carry out this 

activity. This assistance will be 

delivered as a supplement to Program 

Announcement 04065. SAVIR was the 

only recipient of this award and the 

current supplement is consistent with 

the scope of the original announcement. 

Dr. Robert Foss, the Principal 

Investigator, is a leading expert in the 

field of Graduated Drivers Licensing 

(GDL) interventions and has recently 

conducted a similar study using the 

same methodology. Currently, no other 

individual is in a position to conduct 

and evaluate an enhanced enforcement 

intervention, which requires the 

development of specific materials on 

local GDL laws to inform police officers, 

teens, and families about the 

requirements and penalties for GDL 

infractions. Dr. Foss has already 

developed these tools and training 

methods. The time it would take for 

another investigator to accrue the 

knowledge required for this task and set 

up an intervention and evaluation plan 

would set the date of completion back 

considerably and possibly derail the 

project. This work is critical to 

supporting the research agenda and 

CDC’s mission to reduce fatalities and 

injuries to teens from motor vehicle 

crashes. This activity is also 

instrumental in carrying forward the 

research-related goals of the Adolescent 

Trailblazer team. 

C. Funding 

Approximately $231,000 is available 

in FY 2005 to fund this award. It is 

expected that the award will begin on 

October 1, 2005 and will be made for a 

12-month budget period with a project 

period of up to two years. Funding 

estimates may change. 

D. Where To Obtain Additional 

Information 

For general comments or questions 

about this announcement contact: 

Technical Information Management 

Section, CDC Procurement and Grants 

Office, 2920 Brandywine Road, Atlanta, 

GA 30341–4146, Telephone—770–488–

2700. 

For technical questions about this 

program, contact: Arlene Greenspan, 

Project Officer, CDC, National Center for 

Injury Prevention and Control, 4770 

Buford Highway NE., Mailstop K–63, 

Atlanta, GA 30341, Telephone—770–

488–1279, fax—770–488–1317, e-mail—

aig0@cdc.gov. 

Federal Register / Vol. 70, No. 178 / Thursday, September 15, 2005 / Notices 54559 

Dated: September 9, 2005. 

William P. Nichols, 

Director, Procurement and Grants Office, 

Centers for Disease Control and Prevention. 

[FR Doc. 05–18321 Filed 9–14–05; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. 2004N–0486] 

Agency Information Collection 

Activities; Announcement of Office of 

Management and Budget Approval; 

Experimental Study of Health Claims 

on Food Packages 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a collection of information entitled 

‘‘Experimental Study of Health Claims 

on Food Packages’’ has been approved 

by the Office of Management and 

Budget (OMB) under the Paperwork 

Reduction Act of 1995. 

FOR FURTHER INFORMATION CONTACT: 

Peggy Robbins, Office of Management 

Programs (HFA–250), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–1223. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of April 20, 2005 (70 

FR 20568), the agency announced that 

the proposed information collection had 

been submitted to OMB for review and 

clearance under 44 U.S.C. 3507. An 

agency may not conduct or sponsor, and 

a person is not required to respond to, 

a collection of information unless it 

displays a currently valid OMB control 

number. OMB has now approved the 

information collection and has assigned 

OMB control number 0910–0565. The 

approval expires on August 31, 2008. A 

copy of the supporting statement for this 

information collection is available on 

the Internet at http://www.fda.gov/ 

ohrms/dockets. 

Dated: September 7, 2005. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. 05–18283 Filed 9–14–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Cardiovascular and Renal Drugs 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Cardiovascular 

and Renal Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on November 16, 2005, from 8 a.m. 

to 5 p.m. 

Location: Food and Drug 

Administration, CDER Advisory 

Committee Conference Room, rm. 1066, 

5630 Fishers Lane, Rockville, MD. 

Contact Person: Cathy Groupe, Center 

for Drug Evaluation and Research (HFD–

21), Food and Drug Administration, 

5600 Fishers Lane (for express delivery, 

5630 Fishers Lane, rm. 1093), Rockville, 

MD 20857, 301–827–7001, e-mail: 

GroupeC@cder.fda.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512533. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The committee will discuss 

new drug application (NDA) 21–628, 

proposed trade name CERTICAN 

(everolimus) Tablets (0.25 milligrams 

(mg), 0.50 mg, 0.75 mg, and 1.0 mg), 

Novartis Pharmaceuticals Corporation, 

for the proposed indication of 

prophylaxis of rejection in heart 

transplantation. The background 

material will become available no later 

than the day before the meeting and will 

be posted on FDA’s Web site at http:// 

www.fda.gov/ohrms/dockets/ac/ 

acmenu.htm. (Click on the year 2005 

and scroll down to the heading 

Cardiovascular and Renal Drugs 

Advisory Committee.) 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person by November 8, 2005. Oral 

presentations from the public will be 

scheduled between approximately 1 

p.m. and 2 p.m. Time allotted for each 

presentation may be limited. Those 

desiring to make formal oral 

presentations should notify the contact 

person before November 8, 2005, and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Beverly 

O’Neil at 301–827–7001, at least 7 days 

in advance of the meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: September 6, 2005. 

Scott Gottlieb, 

Deputy Commissioner for Policy. 

[FR Doc. 05–18365 Filed 9–14–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Dental Products Panel of the Medical 

Devices Advisory Committee; Notice of 

Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Dental Products 

Panel of the Medical Devices Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on October 11, 2005, from 9:15 

a.m. to 5:45 p.m., and on October 12, 

2005, from 8 a.m. to 5 p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, Ballroom Salons A 

and B, 620 Perry Pkwy., Gaithersburg, 

MD. 

Contact Person: Michael E. Adjodha, 

Center for Devices and Radiological 

Health (HFZ–480), Food and Drug